% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • long_vrts2 long_vrts2 Jun 11, 2014 1:55 PM Flag

    Positive CDX-011 (glemba) results published in pediatric solid cancer preclinical testing:

    1. This was initial testing for extending CDX-011 treatment to GPNMB+ pediatric cancers.
    2. There was a 50% complete response rate in osteosarcoma cancer model.
    3. Response strongly correlated with GPNMB+ expression.
    These results are consisted with, and validate in a pediatric cancer setting, the efficacy results demonstrated by CDX-011 in adult breast cancer.

    Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
    Kolb EA1, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA.

    Author Information
    1A.I. duPont Hospital for Children, Wilmington, Delaware
    2The Children's Hospital at Montefiore, Bronx, New York
    3St. Jude Children's Research Hospital, Memphis, Tennessee
    4Celldex Therapeutics, Needham, Massachusetts
    5Nationwide Children's Hospital, Columbus, Ohio
    6Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland

    Glembatumumab vedotin is an antibody-auristatin conjugate that targets cells expressing the transmembrane glycoprotein NMB (GPNMB, also known as osteoactivin). It has entered clinical evaluation for adult cancers that express GPNMB, including melanoma and breast cancer.
    Glembatumumab vedotin was administered intravenously at a dose of 2.5 mg/kg using a weekly × 3 schedule, and its antitumor activity was evaluated against selected Pediatric Preclinical Testing Program (PPTP) solid tumor xenografts using standard PPTP response metrics.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
17.79-0.32(-1.77%)Nov 24 4:00 PMEST